Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Hepatitis E Vaccine (E. coli, mercury-free vs mercury-containing) Phase IV Trial
CTR20230348Phase 4Completed
- Sponsor
- Wantai BioPharm
- Start
- Feb 2023
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of HEV 239 in hepatitis E (HEV), sponsored by Wantai BioPharm. Started Feb 2023; status: completed.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on CTR20230348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230348.